OVALEAP 300 IU/0.5 ml, solution for injection cartridge, 0.5 ml
Active ingredients: Follitropin alpha
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectioncartridge, 0.5 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- OVALEAP 300 UI/0,5 ml, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 cartouche(s) en verre de 0,5 ml avec 10 aiguille(s)
- Marketing authorisation holder
- THERAMEX IRELAND (IRLANDE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 19 May 2016
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67050131CIP72790302CIP133400927903021Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FOLLITROPINE ALFAsolution | 300 UI · une cartouche de 0,5 mL de solution injectable | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.